Sichuan Huiyu Pharmaceutical (SHA:688553) will conduct clinical trials on the drug HY-2003 after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Wednesday.

The drug contains deoxycholic acid, which aims to reduce adverse reactions at the injection site, shorten the medication interval, accelerate the onset time, and reduce the dosing cycle, the pharmaceutical company said.